Sandoz Inc.

← The SEC Ephemeris: the whole map

Sandoz Inc. EG12014

In the graph: all 3 documents (8 pages).

Application: BLA 761271
Ticker: Sandoz Inc.
Product: EG12014
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: December 9, 2025 · December 5, 2024 · June 24, 2016

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

Pierre Fabre Pharmaceuticals Inc. tabelecleucel®
Polarean Inc. Xenoview
Provention Bio, Inc. PRV-031
Proximagen, LLC Nayzilam
PTC Therapeutics, Inc. vatiquinone
RB Health (US) LLC naproxen sodium |)
Recordati Rare Diseases Inc. Cystadrops
Recro Pharma Inc. Meloxicam
RedHill Biopharma Ltd. Rizaport
Regeneron Pharmaceuticals, Inc. BLA
REGENXBIO, Inc. clemidsogene lanparvovee
Replimune, Inc. vusolimogene oderparepvec
ResQ Pharma
Revance Therapeutics, Inc. daxibotulinumtoxinA
Ricon Pharma, LLC Cyclophosphamide
Rocket Pharmaceuticals, Inc. marnetegragene autotemcel manufactured
Rosemont Pharmaceuticals Holdings, Inc. valacyclovir
Roxane Laboratories, Inc. Cyclophosphamide
Salamandra, LLC rosuvastatin
Samsung Bioepis Co., Ltd. Pyzchiva
Sandoz Inc. EG12014
sanofi-aventis U.S. LLC Fexinidazole
Santen, Inc. Omlonti
Saol International Development Limited sodium dichloroacetate
Sarepta Therapeutics, Inc. Vyondys
Sarfez Pharmaceuticals Inc. pd Pe or to section
Scholar Rock, Inc.
Scienture Inc. losartan potassium
Scilex Pharmaceuticals, Inc. ZTlido
scPharmaceuticals, Inc. Furoscix™ Furosemide)
scPharmaceuticals Services, Inc Furoscix™ “
Sedor Pharmaceuticals, LLC Sesquient
Seikagaku Corporation
Sentynl Therapeutics, Inc. copper histidinate
SFJ Pharmaceuticals, Inc. We have completed our review of this application
Shandong Luye Pharmaceutical Co., Ltd. Rykindo
Shanghai Auzone Biological Technology Co., Ltd. this action below
Shilpa Medicare Limited bortezomib
Spectrum Pharmaceuticals, Inc. SPI-2012
Spes Pharmaceuticals Inc. fosaprepitant

All 283 on the full map →

Group by

Build queue · replay at pipeline speed